We transform any smartphone into a measurement laboratory for precision medicine development
A digital endpoint can reduce sample size and/or augment probability of success (PoS) of R&D proof-of-concept (PoC) trials through two strategies:
Use a digital measurement with higher Signal-to-Noise Ratio (SNR) as a decision-enabling proof-of-concept (PoC) trial endpoint.
Does not have to be fully convergent with reference measurement, while enhancing the end of Phase II decision trees to optimise probability of success (PoS) in Phase III.
Use higher longitudinal frequency of digital measurements that correlate with the reference measurement
These digital markers can then help “explain” the variation, reduce the noise, and increase the SNR for the reference measurement.
Through our multi-year strategic collaboration with Biogen, we aim to expand the reach of our unique technology into Parkinson’s disease, a critical disease area where innovation is crucially needed.
The extension of our work into Parkinson’s disease may cross-fertilize with the progress of our scientific efforts in Multiple Sclerosis.
Indivi's focus on digital endpoint development spans across key neurodegenerative disorders, including Alzheimer’s disease, and related dementias.
Pioneering the future of precision neurology
Indivi and RC2NB are dedicated to unlocking the immense potential of digital measurements in drug development.
Indivi’s close research cooperation with the teams at RC2NB (Co-CEOs Profs. Cristina Granziera and Ludwig Kappos) creates a unique intersection between expert knowledge in Software Development, Data Science, Clinical Science and Advanced Analytics (including Machine Learning and Artificial Intelligence).
The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) is an internationally renowned institution embedded in Basel University Hospital and University of Basel. RC2NB specialises in the development and integration of innovative tools that comprehensively characterise the disease process, thus facilitating the development of better treatments and enabling personalised disease management for people affected by MS and other neuroimmune and neurodegenerative diseases.
More about RC2NB
Your end-to-end scientific research partner in advancing digital endpoints
Indivi is developing and validating user-friendly, reliable, and responsive instruments, spanning across key measurement concepts of interest (COI). By bringing together KonectomTM (licensed from Biogen) and dreaMSMD technologies, Indivi’s platform now includes bespoke instruments for additional COIs such as voice, keystroke dynamics and bradykinesia.
View our technologies